Rack1 elevation enhances chemoresistance in leukemia, hepatocellular carcinoma, and esophageal cancer [39, 41, 43]; Rack1 overexpression promotes targeted therapy resistance in gastrointestinal stromal tumor [42]. This evidence concerns the gene RACK1 and gastrointestinal stromal tumor.